Skip to content

Neurophysiological Correlates of Dissociation Induced by Virtual Reality Hypnosis.

Neurophysiological Correlates of Dissociation Induced by Virtual Reality Hypnosis (VRH) and Hypnosis (HYP) in a Healthy Participants.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05357131
Enrollment
68
Registered
2022-05-02
Start date
2022-06-08
Completion date
2023-06-14
Last updated
2023-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Keywords

Virtual Reality, Hypnosis, Dissociation

Brief summary

Hypnosis and virtual reality are potential tools in treating acute pain. Nevertheless, the neurophysiological correlates of such tools used together, i.e. 'virtual reality hypnosis' (VRH) (Patterson et al., 2004) remain mostly understudied. This study aims to improve our knowledge and understanding of the dissociation (i.e., a mental separation of components of behaviours that normally would be processed together) occurring during VRH. This is a randomized controlled study that will be conducted on healthy participants. As the final goal is to propose such a tool in the clinical context, a clinical application will also be carried out subsequently. Thus the principal outcome is to study dissociation in the context of VRH from a behavioral and neurophysiological point of view. Secondary objectives aim at identifying factors that influence the dissociative effect seen in VRH, as well as measuring traits of hypnotisability, absorption, immersive abilities, dissociation trait and state, pain, and anxiety levels that might impact the effectiveness of such a tool.

Detailed description

The protocol will follow the following steps: 1. Before the experiment: * A medical screening of the medical history and of any concomitant medications will be performed to eligibility. * The 6-item Elkins Hypnotisability Scale (EHS) will be used to assess participant hypnotisability. * Questionnaire sur la Propension à l'Immersion (QPI) will be used to assess participant immersion tendency. 2. Experimental session: Cross-over and within-participant control design i. Visual Analogue Scale (VAS) : * Anxiety. * Pain. ii. EEG Resting-state (5-Min.). iii. EEG VRH or EEG Hypnosis alone (HYP) (15-Min.). iv. Adverse Events (AE) during the protocol will be recorded. v. Narrative recording. vi. VAS : * Dissociation * Absorption * Pain * Anxiety * Arousal/wakefulness * Automaticity vii. Time perception (open question) viii. CyberSickness (CSQ) (only if VRH) ix. Presence Questionnaire x. Satisfaction questionnaire xi. Washout Phase (30-Min.) during which we will administer : * Six-item State-Trait Anxiety Inventory (STAI-6) . * Tellegen Absorption Scale . * Dissociative Experience Scales (DES) . xii. VAS: * Anxiety * Pain xiv. Adverse Events during the protocol will be recorded. xv. Narrative recording. xvi. EEG HYP or EEG VRH Phase (15-Min.). xvii. VAS: * Dissociation * Absorption * Pain * Anxiety * Arousal/wakefulness * Time perception xviii. CSQ (only if VRH) xix. Presence Questionnaire. xx. Satisfaction Questionnaire .

Interventions

BEHAVIORALHypnosis without VR (HYP)

HYP will last for 15 minutes including an induction phase of 5 minutes. The hypnotic audio script Heaven of Peace developped/recorded by Pr. M-E. Faymonville will be used.

DEVICEHypnosis with VR (VRH)

The VRH intervention will use the Aqua video session developed by Oncomfort.

Sponsors

Oncomfort
CollaboratorINDUSTRY
Biowin
CollaboratorUNKNOWN
University of Liege
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Masking description

Methodology of virtual reality hypnosis prevents masking the participants and the experimenter.

Intervention model description

Cross-over and within-participant control design.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

Subject more than 18 years old and equal or less than 65 years old.

Exclusion criteria

1. Low auditory and/or visual acuity precludes the use of the device. 2. Head or face wounds precluding the use of the device. 3. Schizophrenia, dissociative disorder or any other psychiatric disorder. 4. Non-proficiency in French (Research language). 5. Patient under 18 years old. 6. Phobia of deep water. 7. Allergy to cutaneous electrodes. 8. Chronic pain and/or chronic analgesics consumption. 9. Medication affecting the autonomic nervous system. 10. Dizziness.

Design outcomes

Primary

MeasureTime frameDescription
Dissociation stateDuring the procedureCorresponds to a dissociation between the bodily sensations and the actual environment that one feels in a particular situation. will be assessed with a numerical rating scale (0= no dissociation; 10 = dissociation from environment).

Secondary

MeasureTime frameDescription
HypnotisabilityDuring the procedureThe susceptibility one has concerning hypnosis. Will be assessed with the Elkins Hypnotizability Scale. A score : 0-3 : low hypnotizability 4-7: medium hypnotizability 8-11 : high hypnotizability 12 : very high hypnotizability
Absorption traitDuring the procedureThe tendency to become fully involved in a perceptual, imaginative or ideational experience. Will be assessed with the Tellegen Absorption Scale, the higher the score the higher the absorption in the daily life.
Anxiety traitDuring the procedureLevel of anxiety one experiences in one's daily life. Will be assessed with the STAI-6 questionnaire. The higher the score, the higher the anxiety one feels in one's daily life.
Immersion propensity (trait)During the procedureImmersion propensity is the amount of sensory input the virtual reality system creates. Will be assessed with the Immersion Propensity questionnaire. The higher the score, the more one is immersed in the virtual environments.
Anxiety stateDuring the procedureThe amount of anxiety one experiences in a particular situation. Will be assessed with a visual analogy scale. a score = 0 means no anxiety at all, while a score = 10 means most anxiety ever felt.
Absorption stateDuring the procedureThe amount of absroption one experiences in a particular situation. Will be assessed with a numercial rating scale, 0 = no absorption; 10 = fully absorption by the experience.
Dissociation traitDuring the procedureThe amount of dissociation one experiences in one's daily life. Will be assessed with the Dissociative Experience Scale, the higher the score, the more one experiences dissociation in one's daily life.
AutomaticityDuring the procedureA non-voluntary response related to the content of a communication that is intended to be a suggestion. Will be assessed with a numerical rating scale : 0= perfect control; 10 = passive witness.
Arousal/wakefulnessDuring the procedureThe amount of arousal one experiences in a particular situation. Will be assessed with a visual analogy scale, 0=not aroused, awaked; 10 = completely aroused, awake.
Time perceptionDuring the procedureOpen-ended question about one's impression of the duration of the VHR and HYP sessions.
CybersicknessDuring the procedureAssesses the sickness one might experience after the VRH. Will be assessed with the Cybersickness questionnaire. The higher the score, the more one has experience sickness during the VRH.
PresenceDuring the procedureRefers to the degree to which the subject experiences being in the virtual environment. Will be assessed with the presence questionnaire, the higher the score the higher one has the feeling of really being in the virtual environment.
Satisfaction of the participantDuring the procedureAssesses the overall satisfaction one has had with the VRH and HYP session. Will be assessed by a self-made satisfaction questionnaire, the higher the score, the more one is satisfied with the experience.
Pain intensityDuring the procedureThe amount of pain one experiences in a particular situation. Will be assessed with a visual analogy scale, 0= no pain at all; 10= worst pain imaginable.

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026